OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

April 6th 2023

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Dr Hays on Treating Patients With HER2+ CRC

April 6th 2023

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

Dr Callander on Investigational Maintenance Regimens in Multiple Myeloma

April 6th 2023

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

Dr Kuykendall on Emerging Therapies in Systemic Mastocytosis

April 6th 2023

Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.

Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases

April 6th 2023

Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.

Dr Epstein-Peterson on the Treatment of Transplant-Eligible and -Ineligible Patients with MCL

April 6th 2023

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Dr Kuykendall on AEs With Midostaurin and Avapritinib in Advanced Systemic Mastocytosis

April 5th 2023

Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.

Dr Kuykendall on Molecular Testing in Systemic Mastocytosis

April 5th 2023

Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.

Dr Shah on the Investigation of LV20.19 CAR in MCL

April 5th 2023

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr Dawson on Palliative Radiotherapy in Symptomatic HCC or Liver Metastases

April 5th 2023

Laura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.

Dr Albigès on the Efficacy of Cabozantinib in Pretreated RCC

April 5th 2023

Laurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.

Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLC

April 5th 2023

Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.

Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer

April 5th 2023

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.

Updates and Advances in Early Stage Breast Cancer

April 5th 2023

Dr Hays on the Evolution of the Treatment Landscape in HCC

April 4th 2023

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

Dr Kahn on the Investigation of Newcastle Disease Virus With IL-12 in Ovarian Cancer

April 4th 2023

Ryan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.

Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPC

April 4th 2023

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Dr Barber on the Significance of the KEYNOTE-775 Trial for the Second-line Treatment of Endometrial Cancer

April 4th 2023

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

Dr Montes de Oca on the Use of Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancers

April 4th 2023

Mary Katherine Montes de Oca, MD, discusses the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in gynecologic cancers.

Dr. Sadai on Signs and Symptoms of High-Grade Meningiomas

April 4th 2023

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.